EUVIMEDEUVIMED entdecken
Fallbericht

Case reports: Peficitinib efficacy in treating palmoplantar pustulosis induced by paradoxical reactions to golimumab in two rheumatoid arthritis cases

Mari Yamamoto iD, Waka Yokoyama-Kokuryo iD, Hiroki Ikai iD, Tsuyoshi Watanabe iD, Naoho Takizawa iD, Yoshiro Fujita iD

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxaf080 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Mari Yamamoto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Nephrology, Chubu Rosai Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Adamantane, Antibodies, Monoclonal, Antirheumatic Agents, Arthritis, Rheumatoid. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A paradoxical reaction refers to a response opposite to the expected effects of drug therapy. Cutaneous paradoxical reactions, which occur with the use of immunosuppressive drugs, are believed to result from treatment-induced cytokine imbalances. These reactions can manifest as various dermatological conditions, including psoriasis and palmoplantar pustulosis. Currently, no established guidelines exist for reducing or discontinuing biologics in patients with rheumatoid arthritis who experience paradoxical reactions, posing a significant challenge for clinicians managing dermatitis and the underlying diseases. This case report presents two cases of patients with rheumatoid arthritis who developed palmoplantar pustulosis as a paradoxical reaction after treatment with golimumab, a tumour necrosis factor inhibitor. Both patients achieved remission of joint and skin symptoms following treatment with peficitinib, a Janus kinase inhibitor. To the best of our knowledge, this is the first report documenting the successful treatment of paradoxical reaction-induced palmoplantar pustulosis with peficitinib. These findings suggest that peficitinib could serve as an effective alternative when tumour necrosis factor inhibitors are no longer viable. Thus, peficitinib may be a potential therapeutic option for the management of rheumatoid arthritis patients with palmoplantar pustulosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdamantaneAntibodies, MonoclonalAntirheumatic AgentsArthritis, RheumatoidJanus Kinase InhibitorsNiacinamidePsoriasisHumansTreatment Outcome

Stichwörter der Autor:innen

Janus kinase inhibitorsParadoxical reactionpalmoplantar pustulosispeficitinibtumour necrosis factor inhibitors

Substanzen

AdamantaneAntibodies, MonoclonalAntirheumatic AgentsgolimumabJanus Kinase InhibitorsNiacinamidepeficitinib

Autor:innen und Institutionen

  • Department of Rheumatology and Nephrology, Chubu Rosai Hospital, Nagoya, Japan.
  • Infection Control Team, Chubu Rosai Hospital, Nagoya, Japan.
  • Scientific Research WorkS Peer Support Group (SRWS-PSG), Osaka, Japan.

ORCID-Profile: Mari Yamamoto, Waka Yokoyama-Kokuryo, Hiroki Ikai, Tsuyoshi Watanabe, Naoho Takizawa, Yoshiro Fujita

Zitieren

APA

Yamamoto, M., Yokoyama-Kokuryo, W., Ikai, H., Watanabe, T., Takizawa, N., & Fujita, Y. (2025). Case reports: Peficitinib efficacy in treating palmoplantar pustulosis induced by paradoxical reactions to golimumab in two rheumatoid arthritis cases. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf080

Vancouver

Yamamoto M, Yokoyama-Kokuryo W, Ikai H, Watanabe T, Takizawa N, Fujita Y. Case reports: Peficitinib efficacy in treating palmoplantar pustulosis induced by paradoxical reactions to golimumab in two rheumatoid arthritis cases. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf080

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Mari and Yokoyama-Kokuryo, Waka and Ikai, Hiroki and Watanabe, Tsuyoshi and Takizawa, Naoho and Fujita, Yoshiro},
  title = {Case reports: Peficitinib efficacy in treating palmoplantar pustulosis induced by paradoxical reactions to golimumab in two rheumatoid arthritis cases},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxaf080}
}
Kostenlos starten →